Efficacy and safety of rivaroxaban in the treatment of deep vein thrombosis

Abstract

This study aims to present the clinical results of patients administered rivaroxaban for the treatment of deep vein thrombosis (DVT) in terms of efficacy and safety. Methods: A total of 50 patients (30 males, 20 females age range 25 to 88 years) diagnosed with DVT had received rivaroxaban treatment in the department of medicine, Chhattisgarh Institute of Medical Science (CIMS) Bilaspur Chhattisgarh India. between September 2018 and august 2020 were included in the study. Deep vein thrombosis diagnoses of the patients were confirmed by Doppler ultrasonography. The patients' epidemiological and biochemical values were evaluated. Major-minor bleeding and recurrence that occurred during rivaroxaban treatment was investigated. Results: Patients were treated for 3, 6 or 12, months, according to flow up and result. When anticoagulant treatments of the patients were examined, 15 patients (30%) were treated with rivaroxaban as initial treatment and 35 patients (70%) had transitioned from warfarin to rivaroxaban treatment. In patients using rivaroxaban, one patient had hypermenorrhea and two patients had epistaxis. Major bleeding was not detected. While three patients had alanine aminotransferase levels up to two times higher than the normal limit, none of the patients had clinically significant liver or kidney failure. Recurrent DVT or pulmonary embolism was not detected in the patients. Conclusion: According to the current guidelines and literature findings novel oral anticoagulants could be used safely and efficiently as a first line drug therapy in DVT patients due to their non-inferior effectiveness to warfarin and lower side effect profile.